Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143677 | 0.87 | AURKA (0.73) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4138252 | 0.83 | AURKA (0.73) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4133178 | 0.83 | AURKA (0.73) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL5189334 | 0.82 | FGFR1 (0.44) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4945475 | 0.82 | AURKA (0.92) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4133143 | 0.81 | AURKA (0.79) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4130136 | 0.80 | AURKA (0.71) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL5618967 | 0.79 | AURKA (0.68) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4143663 | 0.79 | AURKA (0.71) | AURKAAURKBKDRCHEK1SRC | |
| SCHEMBL4130252 | 0.78 | AURKA (0.69) | AURKAAURKBKDRCHEK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090168953-A1 | Dental x-ray bite block and alignment method | TANYA L. SZOMMER (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| EP-1966213-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068465-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | AAAS, CYP3A5, BRCA1 | AURKA 2294/4885AURKB 2649/4885KDR 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.